MONTREAL, QUEBEC -- (MARKET WIRE) -- December 18, 2006 -- Theratechnologies (TSX: TH) advises of an upcoming conference call and webcast to discuss the results of its Phase 3 clinical trial testing TH9507 in HIV-associated lipodystrophy. The call will be presided over by the President and CEO of Theratechnologies, Mr. Yves Rosconi. Mr. Luc Tanguay, Senior Executive Vice President and Chief Financial Officer and Dr. Koenraad Blot, M.D., Executive Director, Clinical Research, will also be participating.
